ArticleBMJ open2018
Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study.
Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Association between risk of ischemic stroke and liver enzymes levels: a systematic review and meta-analysis.BMC neurology · 2025Pooled it
- Association of alkaline phosphatase to platelet ratio index with ICU mortality in patients with cardiac arrest.BMC cardiovascular disorders · 2026Article
- Employment of the Albumin to Alkaline Phosphatase Ratio to Predict All-cause Mortality and Cardiovascular and Cerebrovascular Mortality in Adults Aged At Least 60 Years: An Analysis From NHANES 2003-2018.Reviews in cardiovascular medicine · 2026Article
- Alkaline phosphatase predicts short-term postoperative outcome in adult patients with moyamoya disease.Frontiers in neurology · 2025Article
- Associations between serum levels of liver function biomarkers and all-cause and cause-specific mortality: a prospective cohort study.BMC public health · 2024Article
- Serum alkaline phosphatase is a strong predictor of mortality in ESKD patients: analysis of the RISCAVID cohort.Journal of nephrology · 2024Observational
- Albumin-to-alkaline phosphatase ratio as a novel prognostic indicator in patients undergoing peritoneal dialysis: a propensity score matching analysis.Frontiers in medicine · 2024Article
- Association between urinary cadmium levels and prevalence of coronary artery disease: NHANES cross-sectional study (2009-2018).Frontiers in cardiovascular medicine · 2024Article
- Impact of alkaline phosphatase on clinical outcomes in patients with ischemic stroke: a nationwide registry analysis.Frontiers in neurology · 2024Article
- Salivary microbiome and hypertension in the Qatari population.Journal of translational medicine · 2023Article
- Elevated Levels of Serum Alkaline Phosphatase are Associated with Increased Risk of Cardiovascular Disease: A Prospective Cohort Study.Journal of atherosclerosis and thrombosis · 2023Article
- An examination of causal associations and shared risk factors for diabetes and cardiovascular diseases in the East Asian population: A Mendelian randomization study.Frontiers in endocrinology · 2023Article
- Serum Alkaline Phosphatase Levels and Increased Risk of Brain Hemorrhage in Hemodialysis Patients: The Q-Cohort Study.Journal of atherosclerosis and thrombosis · 2022Article
- Increased Serum Alkaline Phosphatase and Functional Outcome in Patients with Acute Ischemic Stroke Presenting a Low Ankle-Brachial Index.Journal of atherosclerosis and thrombosis · 2022Article
- Non-Linear Association Between Serum Alkaline Phosphatase and 3-Month Outcomes in Patients With Acute Stroke: Results From the Xi'an Stroke Registry Study of China.Frontiers in neurology · 2022Article
- Predictive biomarkers of cardiovascular disease in adult Canadian population.Journal of diabetes and metabolic disorders · 2021Article
- Alkaline phosphatase-to-albumin ratio as a novel predictor of long-term adverse outcomes in coronary artery disease patients who underwent PCI.Bioscience reports · 2021Article
- Interaction of Serum Alkaline Phosphatase and Folic Acid Treatment on Chronic Kidney Disease Progression in Treated Hypertensive Adults.Frontiers in pharmacology · 2021Article
- Positive Association Between Serum Alkaline Phosphatase and First Stroke in Hypertensive Adults.Frontiers in cardiovascular medicine · 2021Article
- Plasma Inorganic Pyrophosphate Deficiency Links Multiparity to Cardiovascular Disease Risk.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the association of alkaline phosphatase (ALP) levels with the risk of the composite end point of cardiovascular disease (CVD), and all-cause mortality as well as each of them separately.
designProspective cohort study.
settingWithin the framework of the Tehran Lipid and Glucose Study (TLGS) cohort, participants were followed from baseline examination (1999-2001) until March 2014.
participantsA total of 2578 participants, aged ≥30 years free of prevalent CVD at baseline examination. PRIMARY OUTCOME: The main outcome measures were composite end point of coronary heart disease (CHD), stroke, all-cause mortality and each per se.
resultsDuring a median follow-up of 11.3 years, 369, 68, 420, 170 and 495 participants experienced CHD, stroke, CVD, all-cause mortality and the composite outcome, respectively. In the multivariable Cox regression models, the adjusted HRs (95% CI) for mentioned events per one SD increase in ALP level after full adjustment were 1.11 (1.01 to 1.22), 1.20 (0.97 to 1.49, p=0.058), 1.10 (1.01 to 1.21), 1.16 (1.01 to 1.33) and 1.11 (1.02 to 1.21), respectively. Furthermore, participants with ALP levels in the highest tertile had significant adjusted HRs (95% CI) for stroke (1.88 (1.00 to 3.61)), CVD (1.30 (1.01 to 1.68)) and composite outcome (1.27 (1.00 to 1.61)). The cut-off value of ALP ≥199 IU/L for predicting composite outcome was derived using Youden's index, based on which this cut-off point was associated with significant risk of 80%, 26%, 43% and 26% for incident stroke, CVD, all-cause mortality and composite outcome. Additionally, no improvement was seen in the predictive ability of traditional risk factors models after adding ALP values, considering the levels of Akaike information criterion, C-index and Net Reclassification Index.
conclusionIndependent associations between ALP levels and the risks of CVD and mortality events were shown, despite the fact that adding the data of ALP to known risk factors did not improve the prediction of these events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.